Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...
By Beth Senko, CFA NASDAQ:CASI READ THE FULL CASI RESEARCH REPORT CASI Pharmaceuticals (NASDAQ:CASI) signaled a shift in its business strategy in March – focusing its efforts on its hematology franchise and deemphasizing its ANDA portfolio. This change scales back CASI’s initial broad-reaching goal to be the leading provider of high quality proprietary, licensed and ANDA pharmaceuticals to the
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI): CASI Pharmaceuticals, Inc., a pharmaceutical company, develops...
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Solebury Trout Virtual Global Healthcare Series. During the 25-minute presentation, participants will be able to submit questions electronically with answers provided by the discretion of the company on an individual basis afterwards. Details are as follows:
Those following along with CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will no doubt be intrigued by the recent purchase...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Those following along with CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will no doubt be intrigued by the recent purchase...
ROCKVILLE, Md. and BEIJING, Nov. 7, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces an exclusive distribution agreement with Pharmathen Global BV for the development and distribution of octreotide long acting injectable (LAI) microsphere in China. Octreotide LAI formulations are considered a standard of care for the treatment of acromegaly and for the control of symptoms associated with certain neuroendocrine tumors.
ROCKVILLE, Md. and BEIJING , Nov. 12, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical ...
Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.
Market forces rained on the parade of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders today, when the analysts...
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2019, and provided a business update.
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China National Medical Product Administration (NMPA), has approved the clinical trial applications for CNCT19 (CD19 CAR-T) in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) submitted by its partner Juventas Cell Therapy Ltd., a biopharmaceutical company focused on cell therapy (Juventas). CASI previously reported its acquisition of exclusive worldwide commercial rights to CNCT19 from Juventas. Juventas has responsibility for the clinical development of CNCT19.
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders will have a reason to smile today, with the analysts making...
Anyone researching CASI Pharmaceuticals, Inc. (NASDAQ:CASI) might want to consider the historical volatility of the...
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) just released its latest first-quarter results and things are looking...
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2020.